Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for patency of permanent internal jugular dialysis catheters in ESRD
IRCT20220110053680N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in end-stage kidney disease (ESKD) comparing Placebo with Aspirin (2 arms). Primary endpoint: Survival time of permanent internal jugular dialysis catheter. Started Jul 2022; status: completed.
02
Drugs
aspirin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20220110053680N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220110053680N1.